Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human cytomegalovirus immune globulin
- Development stage
- Approved
- Lead developer
- Saol Therapeutics
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Human cytomegalovirus immune globulin is a sterile solution of purified immunoglobulin G (IgG) antibodies derived from pooled adult human plasma with high titers against cytomegalovirus (CMV). It is used for the prophylaxis of CMV disease in patients undergoing organ transplantation, including kidney, lung, liver, pancreas, and heart transplants. The preparation contains predominantly IgG1 and IgG3 subclasses that neutralize the virus and provide tissue protection through complement activation. By increasing anti-CMV antibody levels in at-risk individuals—especially seronegative recipients of organs from seropositive donors—it reduces the incidence and severity of serious CMV disease. It is typically administered intravenously and may be used in combination with antiviral agents such as ganciclovir[1][2][4].
- Brand names
- Cytogam
- Other names
- cytomegalovirus immune globulin intravenous (human)
02
Targets
HCMV surface antigens (Human cytomegalovirus surface antigens)
Beyond the preview
Go deeper on human cytomegalovirus immune globulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human cytomegalovirus immune globulin.